Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
birinapant + carboplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Medivir
- Modality
- Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
**Birinapant + carboplatin + paclitaxel** is a multi-drug chemotherapy combination evaluated primarily in oncology. - **Birinapant** is a small-molecule SMAC (Second Mitochondria-derived Activator of Caspases) mimetic that antagonizes inhibitor of apoptosis proteins (IAPs), thereby promoting apoptosis in cancer cells. - **Carboplatin** is a platinum-based DNA crosslinker used to induce DNA damage leading to apoptosis, and - **Paclitaxel** is a tubulin-binding chemotherapeutic which stabilizes microtubules, causing cell cycle arrest and apoptosis. This combination has shown synergistic effects (particularly birinapant plus paclitaxel) in preclinical cancer models (including ovarian and pancreatic cancer), and sequential or schedule-dependent dosing may optimize efficacy and reduce antagonism between components. Birinapant has been developed by Tetralogic; carboplatin and paclitaxel are generic and manufactured by multiple companies[1][3][5][7][9].
- Other names
- CARBOPLATIN-TAXOL
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))XIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)IAP (Inhibitor of apoptosis protein family)
Beyond the preview
Go deeper on birinapant + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on birinapant + carboplatin + paclitaxel.